Drug intelligence / Profile preview

SP-161

Development stage: Preclinical
Lead developer: Shuttle Pharmaceuticals
Modality: Small Molecules

Overview

SP-161 is a small molecule radiation sensitizer developed by Shuttle Pharmaceuticals. It is currently undergoing preclinical research at Georgetown University, where it is being tested in cell-based and animal xenograft models of breast cancer. This research aims to support future Investigational New Drug (IND)-enabling studies.

Targets

ATM (Ataxia telangiectasia mutated protein)HDAC (HDAC family)

Beyond the preview

Go deeper on SP-161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-161.

Explore the full profile